Science
-
Research updates, July 14
COVID-19 can cause long-term eye disorders, according to a cross sectional study in Nature Communications. Researchers in Sweden assessed 100 people with Long COVID and compared them to 32 people who had COVID-19 and “recovered.”
-
Research updates, July 7
An autopsy study found persistent SARS-CoV-2 virus in the hearts of some people who had died after having COVID-19. A part of the National Institute of Health’s RECOVER program, the researchers shared their unpublished results in a poster at a pathology conference this spring.
-
Research updates, June 30
A recent imaging study in Sage Journals identified metabolic dysfunction in the brains of people with Long COVID who experience PEM. The study assessed 40 people with the disease from a Long COVID clinic with an advanced imaging technique that can detect various cancers and neurologic conditions.
-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say.
-
Research updates, June 23
A new study found that people with Long COVID were significantly more likely to experience cardiovascular disease after COVID-19. Published in Clinical Medicine Insights: Cardiology, researchers assessed a retrospective cohort of over 8,000 people who had a prior SARS-CoV-2 infection, discovering that Long COVID symptoms were associated with higher odds of cardiovascular disease, particularly angina…
-
Research updates, June 16
Two recent studies have added more evidence that the diabetes drug metformin can reduce the risk of Long COVID.
-
Research updates, June 9
A new study published in Alzheimer’s and Dementia found more evidence of alterations associated with Alzheimer’s disease in people with Long COVID. Notably, scientists identified a larger choroid plexus, a region of blood vessels in the brain, as well as reduced cerebral blood flow.
-
Research updates, June 2
The COVID-19 antiviral ensitrelvir (Xocova), was recently approved by the Food and Drug Administration. The oral drug was approved as PEP, or post-exposure prophylaxis, meaning it is taken within 72 hours after coming in contact with someone who has COVID-19.
-
PolyBio’s Spring 2026 symposium: Advancing Long COVID biomarkers and treatments
The PolyBio Research Foundation recently announced new initiatives and centered biomarkers during their latest virtual conference.
-
International ME/CFS Conference roundup: Setbacks and new hopes for therapeutic research
More than 50 experts from around the world presented the latest findings in basic and therapeutic research on myalgic encephalomyelitis (ME) and Long COVID at a conference in Berlin.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
Trans people with Long COVID navigate a new “dark age” in trans health
-
National COVID-19 trends, October 13
-
Research updates, October 13
-
How I built a COVID-safer school that’s become the heart of a more caring community
-
Biological pathways and mechanistic trials centered at new Long COVID conference in Amsterdam
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance